

**Your reference**  
**Our reference**  
**Date**

May 29, 2023

**Appointment of sub-adviser for JPMorgan Funds - China Fund and JPMorgan Funds – Greater China Fund (Individually, the “Underlying Fund”; collectively, the “Underlying Funds”)**

**Zurich Assurance Ltd**  
(a company incorporated  
in England and Wales  
with limited liability)

**Zurich Life Insurance  
(Hong Kong) Limited**  
(a company incorporated in  
Hong Kong with limited liability)

25-26/F, One Island East  
18 Westlands Road  
Island East, Hong Kong

Website: www.zurich.com.hk

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. IF IN DOUBT, PLEASE SEEK PROFESSIONAL ADVICE.

We accept full responsibility for the accuracy of the content of this document. Capitalized terms in this letter have the same meaning as in the Hong Kong Offering Document (the “Offering Document”) of JPMorgan Funds unless otherwise specified.

Dear valued customer,

We are writing to let you know about the changes to the Underlying Funds. You have invested in at least one of the investment choices corresponding to the Underlying Funds, which are listed in the “Which investment choices are affected?” table below under the column “Name and code of the investment choice”.

**Which investment choices are affected?**

<b>Name and code of the investment choice (Individually, the “Investment Choice”; collectively, the “Investment Choices”)</b>	<b>Name of the corresponding Underlying Fund</b>	<b>Applicable scheme (the “Schemes”)</b>
JPMorgan Funds - China Fund (Code: N5USD)	JPMorgan Funds - China Fund	<ul style="list-style-type: none"> <li>• Magnitude</li> <li>• Matterhorn</li> </ul>
JPMorgan Funds - Greater China Fund (Code: N7USD)	JPMorgan Funds - Greater China Fund	

**What is happening?**

We have been notified by JPMorgan Funds (Asia) Limited, as Hong Kong Representative of the JPMorgan Funds, of certain changes to the Underlying Funds.

With effect on and from May 1, 2023, the Investment Manager of the Underlying Funds will appoint JPMorgan Asset Management (Taiwan) Limited as the non-discretionary sub-adviser of the Underlying Funds.

JPMorgan Asset Management (Taiwan) Limited is a company incorporated in Taiwan and authorized by the Taiwan Financial Supervisory Commission to operate securities investment trust business, securities investment consulting business, discretionary investment management business, and other businesses approved by the Taiwan Financial Supervisory Commission.

JPMorgan Asset Management (Taiwan) Limited as sub-adviser will be remunerated by the Investment Manager out of the Annual Management and Advisory Fee received from the Management Company. There is no change to the fee level or cost in managing the Underlying Funds following the appointment of the sub-adviser.

The Offering Document of JPMorgan Funds will be amended accordingly to reflect the above appointment in due course.

**What does this mean to you?**

If you wish to continue to invest in the Investment Choice(s) after considering the changes outlined above, you will not need to take any action. However, if you do not wish to maintain your investment in the Investment Choice(s), you may switch your existing holdings or redirect your future contribution allocations to alternative investment choice(s) by submitting an instruction to us, free of charge.

We recommend that you contact your licensed insurance intermediary in the first instance, who will be able to advise you of the alternative investment choice(s). For information on the fees and charges and the respective risk factors of our range of investment choices, please refer to the product brochure of the respective Schemes and the offering documents of the underlying funds made available by us upon request.

If you have any questions about this letter or your investment in the investment choice(s), please contact your licensed insurance intermediary, or you can call our customer care hotline at +852 2968 2383 or contact us via <http://www.zurich.com.hk/en/customer-services/contact-us> and we will be happy to help.

Yours faithfully,

Zurich Life Insurance (Hong Kong) Limited  
(a company incorporated in Hong Kong with limited liability)

***Note: Please note investments involve risks. The value of any investment and the income from it can fall as a result of market and currency fluctuations and you could get back less than the amount originally invested.***

**就摩根基金 - 中國基金及摩根基金 - 大中華基金 (各稱為「該相關基金」, 統稱為「該等相關基金」) 委任助理顧問**

蘇黎世人壽  
(於英格蘭及威爾斯註冊  
成立之有限公司)

蘇黎世人壽保險 (香港) 有限公司  
(於香港註冊成立之有限公司)

香港港島東華蘭路18號  
港島東中心25-26樓

網址: [www.zurich.com.hk](http://www.zurich.com.hk)

此乃重要函件, 務請閣下即時垂注。閣下如對本函件的內容有任何疑問, 請尋求專業意見。

我們就此函件所轉載資料的準確性承擔全部責任。除非另有訂明, 否則本函件所載詞彙應與摩根基金的香港銷售文件 (「銷售文件」) 所載者具有相同涵義。

親愛的客戶:

我們謹此致函通知閣下有關該等相關基金的變更。閣下已投資於該等相關基金相應的至少一個投資選項, 其列於下表「受影響的投資選項」中「投資選項的名稱及代碼」一欄。

**受影響的投資選項**

投資選項的名稱及代碼 (各稱為「該投資選項」, 統稱為「該等投資選項」)	相應的該相關基金名稱	適用計劃 (「計劃」)
摩根基金 - 中國基金 (代碼: N5USD)	摩根基金 - 中國基金	<ul style="list-style-type: none"> <li>瑞豐投資計劃</li> <li>瑞承投資計劃</li> </ul>
摩根基金 - 大中華基金 (代碼: N7USD)	摩根基金 - 大中華基金	

**修訂事項**

我們已接獲摩根基金的香港代表摩根基金 (亞洲) 有限公司的通知, 對該等相關基金將作出若干變更。

由2023年5月1日 (包括該日在內) 起, 該等相關基金的投資經理人將委任摩根證券投資信託股份有限公司作為該等相關基金的非全權委託助理顧問。

摩根證券投資信託股份有限公司是一間在台灣註冊成立的公司, 獲台灣金融監督管理委員會許可經營證券投資信託業務、證券投資顧問業務、全權委託投資業務及其他經台灣金融監督管理委員會核准業務。

摩根證券投資信託股份有限公司 (作為助理顧問) 的酬金將由投資經理人從管理公司收取的每年管理及顧問費中撥付。於委任助理顧問後, 管理該等相關基金的費用水平或成本並無變化。

摩根基金的銷售文件將於適當時候作出相應修訂, 以反映上述委任。

**對閣下產生的影響**

如閣下在考慮上述變更後仍繼續投資於該等投資選項，則無需就此修訂作出任何行動。倘若閣下不欲繼續投資於該等投資選項，可向本公司遞交轉換現有投資或重新指定未來供款分配至其他投資選項的指示，費用全免。

我們建議閣下首先諮詢閣下的持牌保險中介人，以取得其他投資選項的建議。有關本公司投資選項（包括費用及收費，以及其相關風險因素）的詳情，請參閱相關計劃的產品介紹冊及相關基金的銷售文件，本公司會應要求提供上述銷售文件。

如閣下對本函件或投資選項中的投資有任何疑問，請聯絡閣下的持牌保險中介人。閣下亦可致電 +852 2968 2383 或經由 <http://www.zurich.com.hk/zh-hk/customer-services/contact-us> 聯絡我們，我們將樂意為閣下效勞。

蘇黎世人壽保險（香港）有限公司  
（於香港註冊成立之有限公司）  
2023年5月29日

**註：投資涉及風險，閣下的投資價值及收益可因市場及貨幣波動而下跌，有可能導致閣下不能取回所有投資款項。**